TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ -- Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor Libtayo now approved by the European Commission for three advanced cancers...
from PR Newswire: https://ift.tt/3gS6pMs
No comments:
Post a Comment